Iambic Therapeutics, Inc builds AI-driven platforms to accelerate the discovery of novel medicines for patients with serious diseases. The company's approach integrates physics-informed machine learning, high-throughput experimental automation, and AI-driven drug discovery to advance therapeutic development.
Its Iambic Platform combines these technologies to deliver new drug candidates to human clinical trials with industry-leading speed. Current pipeline assets include IAM1363, a HER2 inhibitor in Phase 1/1b studies for cancer, as well as programs targeting novel mechanisms such as KIF18A allosteric inhibition and selective dual CDK2/4 inhibition.
Iambic Therapeutics has achieved multiple drug candidates across target classes and formed strategic partnerships with leading pharmaceutical companies, including Takeda and Lundbeck. The clinical progress of candidates like IAM1363 demonstrates the platform's capacity to translate AI-driven insights into tangible therapeutic outcomes.
